Free Trial

Phathom Pharmaceuticals (PHAT) Earnings Date, Estimates & Call Transcripts

Phathom Pharmaceuticals logo
$6.06 -0.17 (-2.73%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$6.08 +0.02 (+0.25%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phathom Pharmaceuticals Earnings Summary

Phathom Pharmaceuticals announced Q4 2025 earnings on February 26, 2026, reporting an EPS of -$0.08, which topped analysts' consensus estimates of -$0.09 by $0.01. Quarterly revenue was reported to be $57.58 million, above the consensus estimate of $57.44 million. With a trailing EPS of -$1.03, Phathom Pharmaceuticals' earnings are expected to grow next year, from ($0.31) to $1.11 per share.

Latest Q4
Earnings Date
Feb. 26Estimated
Consensus EPS
(Feb. 26)
-$0.09
Actual EPS
(Feb. 26)
-$0.08 Beat By $0.01
Actual Revenue
(Feb. 26)
$57.58M

Q4 2025 Earnings Resources

Get Phathom Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

PHAT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PHAT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Phathom Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate
($0.31) EPS
Next Year EPS Consensus Estimate
$1.11 EPS

Phathom Pharmaceuticals Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
2/26/2026Q4 2025-$0.09-$0.08+$0.01-$0.29$57.44M$57.58M
10/30/2025Q3 2025-$0.30-$0.15+$0.15-$0.41$47.03M$49.50M

Phathom Pharmaceuticals Earnings - Frequently Asked Questions

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earning data on Thursday, February 26, 2026. Learn more on PHAT's earnings history.

In the previous quarter, Phathom Pharmaceuticals (NASDAQ:PHAT) reported ($0.08) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.09) by $0.01. Learn more on analysts' earnings estimate vs. PHAT's actual earnings.

The conference call for Phathom Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Phathom Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded annual revenue of $175.11 million.

Phathom Pharmaceuticals (NASDAQ:PHAT) has a recorded net income of -$221.25 million. PHAT has generated -$1.03 earnings per share over the last four quarters.

Phathom Pharmaceuticals' earnings are expected to grow from ($0.31) per share to $1.11 per share in the next year.


Earnings data for NASDAQ:PHAT is sourced from Fiscal.ai, with the most recent quarter reported on 2/26/2026. New results are added as companies report their earnings.
From Our Partners